<DOC>
	<DOCNO>NCT00698815</DOCNO>
	<brief_summary>This randomized phase II trial study pemetrexed disodium sunitinib malate compare well work give alone together second-line therapy treat patient stage IIIB stage IV non-small cell lung cancer . Drugs use chemotherapy , pemetrexed disodium , work different way stop growth tumor cell , either kill cell stop dividing . Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether pemetrexed disodium sunitinib malate effective give alone together treat non-small cell lung cancer .</brief_summary>
	<brief_title>Pemetrexed and/or Sunitinib Second-Line Therapy Treating Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate 18 week progression-free survival rate pemetrexed ( pemetrexed disodium ) alone ( Arm I ) , sunitinib ( sunitinib malate ) alone ( Arm II ) pemetrexed plus sunitinib ( Arm III ) second-line set advanced non-small cell lung cancer ( NSCLC ) . SECONDARY OBJECTIVES : I . To compare progression-free survival three arm . II . To estimate response rate , duration response , rate stable disease , overall survival characterize toxicity profile three arm . III . To estimate response rate , duration response , rate stable disease , overall survival toxicity sunitinib patient Arm I receive regimen third line set . IV . To assess vascular endothelial growth factor ( VEGF ) haplotypes advanced non-small cell lung cancer . V. To test change tumor size 6 week ( 2 cycle therapy , typically first evaluation point type study ) early predictor therapeutic activity second-line treatment non-small cell lung cancer . OUTLINE : Patients randomize 1 3 treatment arm . ARM I : Patients receive pemetrexed disodium intravenously ( IV ) 10 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients document disease progression may receive sunitinib malate Arm II third-line therapy . ARM II : Patients receive sunitinib malate orally ( PO ) daily ( QD ) day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients document disease progression may receive pemetrexed disodium Arm I third-line therapy . ARM III : Patients receive pemetrexed disodium IV 10 minute day 1 sunitinib malate PO QD day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients document disease progression may receive third-line therapy discretion treat physician . After completion study treatment , patient follow every 6 week disease progression every 6 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic documentation : histologic cytologic documentation NSCLC Stage : IIIB/IV evidence disease progression follow firstline therapy Tumor site : lung ( nonsmall cell ) No cavitary lesion Only one prior chemotherapy regimen firstline stage IIIB/IV setting allow ; could either platinum nonplatinumbased regimen Firstline therapy must complete &gt; = 28 day registration Prior adjuvant therapy allow provided patient one previous regimen advance stage IIIB/IV setting At least 28 day prior major surgery least 14 day prior radiotherapy registration No prior inhibitor VEGF receptor ( VEGFR ) ( e.g. , SU5416 , SU6668 , AZ6474 , SU11248 , PTK787 , AZD2171 , AEE788 , sorafenib ) ; prior treatment epidermal growth factor receptor ( EGFR ) inhibitor bevacizumab allow , provide least 4 week elapse No prior pemetrexed Patients must measurable nonmeasurable disease Measurable disease Lesions accurately measure least one dimension ( long diameter record ) &gt; = 2 cm conventional technique &gt; = 1 cm spiral compute tomography ( CT ) scan Nonmeasurable disease All lesion , include small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) truly nonmeasurable lesion Lesions consider nonmeasurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Pregnant nursing mother eligible study ; patient child bear year must baseline negative pregnancy test ( case female ) ; male female must practice appropriate contraceptive measure period protocol therapy 6 month completion protocol therapy ; appropriate method birth control include abstinence , oral contraceptive , implantable hormonal contraceptive ( Norplant ) , double barrier method ( diaphragm plus condom ) No ongoing cardiac dysrhythmias , atrial fibrillation , history correct QT interval ( QTc interval ) &gt; 500 msec ( within 2 year prior registration ) ; use agent proarrhythmic potential ( e.g. , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide , flecainide ) recommend protocol therapy Patients class I New York Heart Association ( NYHA ) heart failure eligible ; patient history class II NYHA heart failure eligible , provided meet least one follow criterion : Patients history class II heart failure asymptomatic treatment Patients prior anthracycline exposure Patients receive central thoracic radiation include heart radiotherapy port Patients history symptomatic congestive heart failure within 12 month prior entry eligible No myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft stenting , cerebrovascular accident transient ischemic attack within last year Patients hypertension control medication ( &gt; 150/100 mmHg despite optimal medical therapy ) eligible Patients require use therapeutic anticoagulation thromboembolic disease eligible ; Note : low dos Coumadin ( 2 mg daily ) permit prophylaxis thrombosis No history venous thrombosis , pulmonary embolism , hypercoagulopathy syndrome No history pulmonary hemorrhage , bleed diathesis , evidence hemoptysis ; patient bloodtinged bloodstreaked sputum permit study hemoptysis amount less 5 mL blood per episode le 10 mL blood per 24hour period best estimate investigator Patients history hypothyroidism hyperthyroidism eligible , provide currently euthyroid None follow within 28 day begin treatment : abdominal fistula , gastrointestinal perforation , intraabdominal abscess , serious nonhealing wound , ulcer , bone fracture The use follow specific inhibitor inducer cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) permit ; follow inhibitor CYP3A4 prohibit within 7 day treatment sunitinib : azole antifungal ( ketoconazole , itraconazole ) , diltiazem , clarithromycin , erythromycin , verapamil , delavirdine , human immunodeficiency virus ( HIV ) protease inhibitor ( indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) ; follow inducer CYP3A4 prohibit within 12 day begin treatment sunitinib : rifampin , rifabutin , carbamazepine , phenobarbital , phenytoin , St. John 's Wort , efavirenz , tipranavir Other inhibitor inducer CYP3A4 may use necessary , use discourage No symptomatic untreated central nervous system ( CNS ) metastases ; patient CNS metastasis must asymptomatic , must receive definitive therapy ( &gt; = 6 week since resection &gt; = 2 week since radiotherapy ) brain metastasis , steroid stable dose 2 week prior registration No chronic daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory agent know inhibit platelet function ; treatment dipyridamole ( Persantine ) , ticlopidine ( Ticlid ) , clopidogrel ( Plavix ) and/or cilostazol ( Pletal ) allow No pleural effusion ascites detectable physical exam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>